Methods: Service-level data was used from 996 adults with laboratory confirmed COVID-19 who presented to the Queen Elizabeth Hospital Birmingham, UK, from March to June 2020. All individuals were categorized into DM+C, DM-NC, and non-diabetes groups. Physiological and laboratory measurements in the first 5 days after admission were collated and compared among groups. Cox proportional hazards regression models were used to evaluate associations between diabetes status and the risk of mortality.
Results: Among the 996 individuals, 104 (10.4%) were DM+C, 295 (29.6%) DM-NC and 597 (59.9%) non-diabetes. There were 309 (31.0%) in-hospital deaths documented, 40 (4.0% of total cohort) were DM+C, 99 (9.9%) DM-NC and 170 (17.0%) non-diabetes. Individuals with DM+C were more likely to present with high anion gap/metabolic acidosis, features of renal impairment, and low albumin/lymphocyte count than those with DM-NC or those without diabetes. There was no significant difference in mortality rates among the groups: compared to individuals without diabetes, the adjusted HRs were 1.39 (95% CI 0.95–2.03, p = 0.093) and 1.18 (95% CI 0.90–1.54, p = 0.226) in DM+C and DM-C, respectively.
Conclusions: Those with COVID-19 and DM+C presented with a more severe clinical and biochemical profile, but this did not associate with increased mortality in this study.
Bibliographical noteFunding Information:
SAM has received research support from Novo Nordisk Research Foundation UK and Academy of medical Sciences. SB has received grants, personal fees, and support to attend educational meetings from Novo Nordisk; grants from The Binding Site; personal fees from AstraZeneca, Merck, Sharpe & Dohme, and Janssen; personal fees and support to attend educational meetings from Boehringer Ingelheim; personal fees and support to attend educational meetings from Eli Lilly; and personal fees and support to attend educational meetings from Sanofi‐Aventis and NAPP. WH has received Received Research Grants, Travel Grant and Consultancy for following AZ, BI, Eli Lilly, Jansen, Novo Nordisk, Sanofi, NAPP and MSD. Other authors have no declarations.
© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism